Do calcium channel blockers increase the risk of cancer?

American Journal of Hypertension

Volumn 9, Issue 7, 1996, Pages 695-699

  Pahor, Marco ^a,c   Guralnik, Jack M ^b   Salive, Marcel E ^b   Corti, Maria Chiara ^b   Carbonin, Pierugo ^a   Havlik, Richard J ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

angiotensin converting enzyme inhibitors; apoptosis; Calcium channel blockers; cancer; diltiazem; hypertension; neoplasms; nifedipine; verapamil; blockers

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NIFEDIPINE; VERAPAMIL;

AGED; AGING; ANTIHYPERTENSIVE ACTIVITY; APOPTOSIS; ARTICLE; BODY MASS; CANCER GROWTH; CANCER RISK; CIGARETTE SMOKING; COMPLICATION; DOSE RESPONSE; FEMALE; GROWTH REGULATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT;

EID: 0030199181     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-7061(96)00186-0     Document Type: Article

References (38)

1. 1. Raderer M, Scheithauer W: Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 1993;72:3553-3563.
2. 2. Milroy R: A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. Br J Cancer 1993;68:813-818.
3. 45Ca influx and cellular growth of human prostatic tumor cells. Prostate 1991; 19:299-311.
4. 4. Whitfield JF: Calcium signals and cancer. Crit Rev Oncogen 1992;3:55-90.
5. 5. Carson DA, Ribeiro JM: Apoptosis and disease. Lancet 1993;341:1251-1254.
6. 6. Martin SJ, Green DR: Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol Hematol 1995;18:137-153.
7. 7. Trump BF, Berezesky IK: Calcium-mediated cell injury and cell death. FASEB J 1995;9:219-228.
8. 8. Furberg CD, Pahor M, Psaty BM: The unnecessary controversy. Eur Heart J (in press).
9. 9. Pahor M, Guralnik JM, Corti C, et al: Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43:1191-1197.
10. 10. Pahor M, Guralnik JM, Furberg CD, et al: Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347:1061-1065.
11. 11. Cornoni-Huntley J, Ostfeld AM, Taylor JO, et al: Established Populations for Epidemiologiec Studies of the Elderly: study design and methodology. Aging Clinical and Experimental Research 1993;5:27-37.
12. 12. International Classification of Diseases, 9th revision, Clinical Modification. Washington, DC, Public Health Service-Health Care Financing Administration, 1980.
13. 13. Pahor M, Guralnik JM, Salive ME, et al: Physical activity and risk of severe gastrointestinal hemorrhage in older persons. JAMA 1994;272:595-599.
14. 14. Pahor M, Guralnik JM, Salive ME, et al: Disability and severe gastrointestinal hemorrhage. A prospective study of community dwelling older persons. J Am Geriatr Soc 1994;42:816-825.
15. 15. Pahor M, Chrischilles EA, Guralnik JM, et al: Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 1994;10:405-411.
16. 16. Pahor M, Guralnik JM, Carbonin PU, et al: Acohol consumption and risk of pulmonary embolism and deep venous thrombosis in older persons. J Am Geriatr Soc (in press).
17. 17. Cutler SJ, Ederer F: Maximum utilization of the life-table method in analyzing survival. J Chronic Dis 1958; 8:699-713.
18. 18. Cox DR: Regression models and life tables. J Roy Statist Soc 1972;34B:187-220.
19. 19. Sah VP, Attardi LD, Mulligan GJ, et al: A subset of p53-deficient embryos exhibit exencephaly. Nature Genetics 1995;10:175-180.
20. 20. Zakeri ZF, Ahuja HS: Apoptotic cell death in the limb and its relationship to pattern formation. Biochem Cell Biol 1994;72:603-613.
21. 21. Tenniswood MF, Guenette RS, Lakins J, et al: Active cell death in hormone-dependent tissues. Cancer Metast Rev 1992;11:197-220.
22. 22. Mountz JD, Wu J, Cheng J, Zhou T: Autoimmune dis-ease. A problem of defective apoptosis, Arthritis Rheum 1994;37:1415-1420.
23. 23. Beilharz EJ, Williams CE, Drâgunow M, et al: Mechanisms of delayed cell death following hypoxic-ischemic injury in the immature rat: evidence for apoptosis during selective neuronal loss. Brain Res Mol Brain Res 1995;29:1-14.
24. 24. Gottlieb RA, Burleson KO, Kloner RA, et al: Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994;94:1621-1628.
25. 25. Isner JM, Kearney M, Bortman S, Passeri J; Apoptosis in human atherosclerosis and restenosis. Circulation 1995;91:2703-2711.
26. 26. Bennett MR, Evan GI, Schwartz SM: Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 1995;95:2266-2274.
27. 27. Wright SC, Zhong J, Zheng H, Larrick JW: Nicotine inhibition of apoptosis suggests a role in tumor promotion. FASEB J 1993;7:1045-1051.
28. 28. Maneckjee R, Minna JD: Opioids incluce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ 1994;5:1033-1040.
29. 29. Daling JR, Sherman KJ, Hislop TG, et al: Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol 1992;135:180-189.
30. 30. Daling JR, Sherman KJ: Relationship between human papillomavirus infection and tumours of anogenital sites other than the cervix. IARC Sci Publ 1992;223-241.
31. 31. Lopez Abente G, Gonzalez CA, et al: Tobacco smoke inhalation pattern, tobacco type, and bladder cancer in Spain. Am J Epidemiol 1991;134:830-839.
32. 32. Connor J, Sawczuk IS, Benson MC, et al: Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate 1988;13:119-130.
33. 2+ channels exposed to serum from patients with type I diabetes. Science 1993;261:86-90.
34. 2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB J 1993;7:453-463.
35. 35. Garland C, Shekelle RB, Barrett-Connor E, et al: Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet 1985;i:307-309.
36. 36. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al: Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (IN-TACT). Lancet 1990;335:1109-1113.
37. 37. Furberg CD, Psaty BM, Meyer JV: Nifedipine. Doserelated increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331.
38. 38. Opie LH: Myocardial Protection by Calcium Antagonists, New York, Authors' Publishing House, 1994.